Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eosinophilia associated with bupropion

M A Malesker1, G S Soori, P M Malone

  • 1Immanuel Medical Center, Omaha, NE, USA.

The Annals of Pharmacotherapy
|September 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Suppression of SCARA5 by Snail1 is essential for EMT-associated cell migration of A549 cells.

Oncogenesis·2013
Same author

A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422).

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

Chemo-biotherapy with 5-fluorouracil, leucovorin, and alpha interferon in metastatic carcinoma of the colon--a Cancer Biotherapy Research Group [CBRG] phase II study.

Cancer biotherapy & radiopharmaceuticals·2000
Same author

Electronic prescriptions in pharmacy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2000
Same author

Extravasation of i.v. promethazine.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1999
Same author

Rhodesian trypanosomiasis in a splenectomized patient.

The American journal of tropical medicine and hygiene·1999
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
Same journal

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.

The Annals of pharmacotherapy·2026
Same journal

A Comparison of Phenobarbital Dosing Strategies for the Treatment of Alcohol Withdrawal Syndrome.

The Annals of pharmacotherapy·2026
See all related articles

This case study reports the first known instance of eosinophilia, a condition marked by elevated eosinophils, linked to bupropion medication. The patient

Area of Science:

  • Pharmacology
  • Hematology
  • Clinical Medicine

Background:

  • Bupropion is an antidepressant medication.
  • Eosinophilia is an increase in eosinophils, a type of white blood cell.
  • Medication-induced eosinophilia is a known phenomenon.

Observation:

  • A 72-year-old woman developed significant eosinophilia (absolute count 6693 x 10(6)/L) after 5 days of bupropion therapy.
  • Other potential causes for eosinophilia were systematically excluded.
  • Eosinophil levels rapidly decreased after bupropion was discontinued.

Findings:

  • This case represents the first documented incidence of eosinophilia associated with bupropion.
  • The temporal relationship strongly suggests bupropion as the causative agent.

Related Experiment Videos

  • The exact mechanism linking bupropion to eosinophilia remains undetermined.

    • Implications:

    • Clinicians should consider bupropion as a potential cause of eosinophilia.
    • This finding expands the known adverse drug reactions associated with bupropion.
    • Further research may be warranted to elucidate the underlying pathophysiology.